MEK inhibitors for the treatment of NRAS mutant melanoma.
Publication/Presentation Date
1-1-2018
Abstract
Melanoma is increasing rapidly in incidence and prevalence, especially in younger females and older males. Treatment options have expanded beyond high-dose interleukin 2 and adoptive T-cell therapy to include inhibitors of immune checkpoints programmed death 1 (PD-1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and small molecular inhibitors of pathways activated in melanoma, in particular the mitogen-activated protein kinase (MAPK) pathway. PD-1/CTLA-4 inhibitors and inhibitors of MAPK such as BRAF/MEK inhibitors have significantly improved survival in both the metastatic and, more recently, adjuvant settings. In this review, we discuss the preclinical data, clinical development, and potential use of novel MEK inhibitor binemetinib, particularly in the setting of
Volume
12
First Page
2553
Last Page
2565
ISSN
1177-8881
Published In/Presented At
Sarkisian, S., & Davar, D. (2018). MEK inhibitors for the treatment of NRAS mutant melanoma. Drug design, development and therapy, 12, 2553–2565. https://doi.org/10.2147/DDDT.S131721
Disciplines
Medicine and Health Sciences
PubMedID
30154648
Department(s)
Fellows and Residents
Document Type
Article